ZYP Medical

What ZYP Medical prescribes, by goal

Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

What it claims, and what it cites

The outcome claims are borrowed from brand-name trials and labeled that way. The FAQ gives semaglutide as roughly 10 to 15% average body-weight loss and tirzepatide as 15 to 22%. It calls those published trial averages, and adds that results vary and are not guaranteed. No study is linked beside either range. The quality claim is specific but unevidenced on the page. The site says every prescription is filled by a 503A pharmacy that verifies the potency of each batch. The peptide page adds testing for potency and sterility. No certificate of analysis, batch record or lab name is published. One marketing claim sits awkwardly beside the site's own terms. The weight-loss page says ZYP does not run ads and grows by referral. The terms of use describe retargeting cookies used to show ads to past visitors. The peptide copy is more candid than most. It says much of the research behind these compounds is preclinical, and that ZYP guarantees no result. It also concedes that ZYP will not be the cheapest option. The tesamorelin card calls it the only GHRH analog on the page with FDA approval in any population. That approval belongs to the brand product, and ZYP sells a compounded vial.

Sold by ZYP Medical, not listed here

BPC-157

On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

TB-500

On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

KPV

On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

Ipamorelin

"Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.

CJC-1295

On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.

Tesamorelin

Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.

5-Amino-1MQ

On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).

BPC-157, as an injection, capsules and in the Wolverine stack

On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

TB-500 (thymosin beta-4)

On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

KPV, alone and with BPC-157

On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

Ipamorelin / CJC-1295

"Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.

Compounded tesamorelin, alone and in stacks

Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.

5-Amino-1MQ, alone and with NMN

On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).

GHK-Cu injection

Injectable GHK-Cu is on no FDA compounding list; only non-injectable GHK-Cu is under evaluation, so the cream is listed and the injection is not.

Chewable tirzepatide tablets

Priced at $199 for 30 tablets, but the provider sets the dosing frequency, so the page states no supply length to compare.

Other sellers for weight

• 50 Stars Health

  Also prescribes Semaglutide, Tirzepatide.

  Visit 50 Stars Health →Read the 50 Stars Health review

• Actin

  Also prescribes Semaglutide, Tirzepatide.

  Visit Actin →Read the Actin review

• AgelessRx

  Also prescribes Semaglutide, Tirzepatide.

  Visit AgelessRx →Read the AgelessRx review